IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in breast cancer

7^th International Conference and Expo on Molecular & Cancer Biomarkers

September 15-16, 2016 Berlin, Germany

Chang Gong, Wei-Ge Tan, Wei Luo, Wei-Juan Jia, Ge-Hao Liang, Xin-Hua Xie, Er-Wei Song and Feng-Xi Su

Sun Yat-Sen University, China

Posters & Accepted Abstracts: J Mol Biomark Diagn

Abstract :

The predictive value of a combined four immunohistochemical marker score (IHC4 score) for neoadjuvant chemotherapy (NAC) remains unclear. This study aimed to investigate the predictive value of IHC4 score in predicting pathological complete response (pCR) after NAC in patients with breast cancer (BC). In the present study, we retrospectively reviewed 443 BC patients with NAC and identified a significant association between the IHC4 score prior to NAC and a pCR in the entire cohort. A stratified analysis demonstrated that a high IHC4 score was correlated with a high pCR rate in the patients with ERpositive, small tumor size and anthracycline and taxanes-based regiment (ET) administration. Multivariate analysis showed the IHC4 score was an independent predictive factor for a pCR. ROC analysis demonstrated that IHC4 score exhibited an increased predictive accuracy for a pCR compared with other clinicopathological factors. This study provides a strong rationale for further prospective clinical trials to validate the IHC4 score as a biomarker to predict the clinical response of NAC, which will facilitate the identification of individuals who may receive the most benefit from NAC.

Biography :

Email: changgong282@163.com